english.prescrire.org > Topics > Advancing healthcare policy > Direct-to-consumer advertising (DTCA) disguised as patient "information" [2007-2012] > Actions

Advancing healthcare policy

Direct-to-consumer advertising (DTCA) disguised as patient "information" [2007-2012]

Advancing healthcare policy

Chronological recap of actions
Actions presented by theme

Direct-to-consumer advertising (DTCA) disguised as patient "information" [2007-2012]: Actions

To ensure that patients' rights are respected: yes to reliable independent information, no to direct-to-consumer advertising (DTCA) masquerading as "information", "compliance support"or other types of "health education".

Direct-to-consumer advertising of prescription drugs: European Commission persists in putting industry's interests first (January 2013)

In the latest version of its proposals released in February 2012, the European Commission persists in placing the interests of the pharmaceutical industry before those of patients and public health. Read on...
Revised proposals on "information" to patients: Still an open door to advertising of prescription-only medicines by pharmaceutical companies (October 2011)

In a joint analysis, the International Society of Drug Bulletins (ISDB) and the Medicines in Europe Forum argue that direct-to-consumer "information" on prescription medicines by manufacturers exposes citizens to misleading messages, puts public health at risk and threatens Member States’s social protection systems. Read on...
Towards direct-to-consumer advertising for prescription drugs?
The autumn will be crucial (continued) (November 2010)

The European Commission's original proposals, though improved by the Members of the European Parliament, are still of little benefit and some provisions are even detrimental. Read on...
Towards direct-to-consumer advertising of prescription drugs in Europe? Upholding patients' rights to reliable information (July 2010)

In a joint briefing paper, the Medicines in Europe Forum, Health Action International (HAI) Europe and the International Society of Drug Bulletins (ISDB) urge MEPs to vote for amendments aimed at enhancing patients' access to non-promotional, independent and comparative information. The strict ban on direct-to-consumer advertising must also be upheld. Read on...

In brief
What is at stake, and our counterproposals
Actions
The Legislative Process
The US experience
- Direct-to-consumer advertising of prescription drugs: harmful and difficult to regulate (1/2008)
- Direct-to-consumer advertising for prescription drugs: abuse and confusion
Back to the list of themes

Sitemap |
Terms of use |
Contact
|Top of page